Reported Saturday, Syndax's Revuforj (Revumenib) Achieves High Response Rates In Acute Leukemia Trials, Presents Compelling Data At ASH 2024
Reported Saturday, Syndax's Revuforj (Revumenib) Achieves High Response Rates In Acute Leukemia Trials, Presents Compelling Data At ASH 2024
据报道，Syndax的Revuforj（Revumenib）在急性白血病试验中取得了高响应率，并在2024年ASH大会上展示了引人注目的数据。
- 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML –
- 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –
- Responses were rapid, durable and observed across all major subgroups in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –
- Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting –
- SAVE试验研究中，revumenib与venetoclax和decitabine/cedazuridine联合应用，在R/R AML中达到82%的ORR（33份中的27份）和48%的CR/CRh（33份中的16份）
- AUGMENt-101中扩展数据集显示，KMT2Ar急性白血病R/R患者中，64%的ORR（97份中的62份）和23%的CR/CRh（97份中的22份），MRD阴性率高，可以进行HSCt，数据显示在所有主要亚组中观察到快速、持久的反应
- AUGMENt-101中扩展数据集中的R/R KMT2Ar急性白血病患者，反应迅速、持久，且在所有主要亚组中都有观察到
- 最新数据突出revumenib引人注目的临床概况，并支持进入前线组合试验
资讯热榜
更新时间